XETRA - Delayed Quote EUR

Zoetis Inc. (ZOE.DE)

Compare
160.64
+0.94
+(0.59%)
At close: January 10 at 5:35:44 PM GMT+1

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Ms. Kristin C. Peck CEO & Director 3.45M 5.07M 1971
Mr. Wetteny N. Joseph CPA Executive VP & CFO 1.56M -- 1972
Ms. Wafaa Mamilli EVP & Group President for China, Brazil and Preci. Animal Health 1.32M -- 1967
Dr. Robert J. Polzer Ph.D. Executive VP and President of Research & Development 1.15M 52.79k 1969
Mr. Keith Sarbaugh Executive VP & Chief Digital and Technology Officer -- -- --
Mr. Steven Frank Vice President of Investor Relations -- -- --
Ms. Roxanne Lagano Executive VP, General Counsel & Corporate Secretary -- -- 1965
Mr. William Price VP & Chief Communications Officer -- -- --
Ms. Julie A. Fuller Executive VP, Chief Human Resources Officer & Global Operations -- -- 1972
Ms. Jeannette Ferran Astorga Executive VP of Corporate Affairs & Communications and Chief Sustainability Officer -- -- 1975

Zoetis Inc.

10 Sylvan Way
Parsippany, NJ 07054
United States
973 822 7000 https://www.zoetis.com
Sector: 
Healthcare
Full Time Employees: 
14,100

Description

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Corporate Governance

Zoetis Inc.’s ISS Governance QualityScore as of January 1, 2025 is 2. The pillar scores are Audit: 3; Board: 1; Shareholder Rights: 7; Compensation: 2.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

January 21, 2025 at 12:00 AM UTC

Ex-Dividend Date

February 13, 2025 at 1:30 PM UTC

Zoetis Inc. Earnings Date

Recent Events

Related Tickers